Follow on Google News News By Tag * Biosimilars * Biosimilar * Biosimilar Drugs * Follow-on Biologics * Follow-on Biologic * Biogenerics * Generic Drugs * More Tags... Industry News News By Location Country(s) Industry News
Follow on Google News |  Brand new Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 reportRecently published report Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 will provide you with information that you need to understand current trends and future possibilities for those drugs.
By: Visiongain Ltd. – opportunities and challenges in this emerging market with high potential In 2009, the biological (biologic) drug market generated over $125bn in revenues worldwide. There is great demand for lower-cost biological drugs. Commercial and regulatory developments will make biosimilars and follow-on biologics seize market share - our new report explains how. Many biologic patents will expire during our forecast period. There is mounting pressure from governments, insurers and patients' groups to reduce drug costs. Biologic drugs - noted as some of the most-expensive medicines - are prime targets. Developments facilitating biosimilars/ Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 will provide you with information that you need to understand current trends and future possibilities for those drugs. This report predicts how the biosimilars market will develop from 2010 onwards. We discuss the biosimilar/follow- • Monoclonal antibodies • Fusion proteins • Erythropoietin • Growth hormones • Insulin products • Colony stimulating factors and interleukin- • Interferons We discuss prospects for each class, with biosimilar/follow- Comprehensive analysis of the biosimilars/ Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 examines that sector through a comprehensive review of information sources. We use primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including SWOT analysis. There are over 70 tables and figures included, as well as four interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work. Why you should buy Biosimilars and Follow-On Biologics: Global Market Outlook 2010-2025 This report gives you the following benefits in particular: • You will receive forecasts for the global biosimilar/follow- • You will identify biologic drugs with potential for biosimilar development • You will examine the driving forces, restraints, competition and opportunities facing participants in the biologic and biosimilar sectors • You will receive analysis of biosimilar legislation and regulatory guidance in the US, Europe and Japan – with existing and emerging trends discussed • You will investigate R&D developments in that sector, with up-and-coming trends highlighted • You will examine prospects for leading companies • You will discover interviews with experts regarding the present and future of the sector • You will find out how the biosimilars sector is progressing worldwide – technologically and commercially – and what the future holds. You can obtain this report today Nobody with an interest in the biological or blockbuster drug sectors should overlook our new study. We predict upheaval in the market for biotechnological drugs in the years ahead, as biologicals face increasing competition. This report provides information to help you benefit from that changing market. Do you want to harness those opportunities? Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6 Companies Listed 3SBio Abbott Abraxis BioScience Alexion Pharmaceuticals Amgen Amphastar Pharmaceuticals Apotex AstraZeneca Avesta Biotherapeutics and Research (ABRPL) Avesthagen AxiCorp Barr [acquired by Teva in 2008] Bayer Beijing Shuanglu BIOCEUTICALS Arzneimittel Biocon Biogen Idec BioPartners [acquired by Bioton in 2007] Biotechnology Industry Organization (BIO) [US] Bioton Bristol-Myers Squibb CCL Pharmaceuticals CinnaGen Cipla CJ Corporation CoGenesys [acquired by Teva in 2008] CSL CT Arzneimittel Daiichi Sankyo Dong-A Dr. Reddy’s Laboratories Eden Biodesign Elan Corporation Eli Lilly European Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency (EMEA) Feron Food and Drug Administration (FDA) [US] Fraunhofer Institute [Germany] Genentech Generic Pharmaceutical Association (GPhA) [US] GeneScience Pharmaceutical Getz Pharma GlaxoSmithKline (GSK) GTC Biotherapeutics Halozyme Therapeutics Hexal [acquired by Novartis in 2005] Hospira Hualida Biotech Human Genome Sciences Insmed Intas Biopharmaceuticals Ipsen Pharma Johnson & Johnson Kissei Pharmaceutical Co. Kyowa Hakko Kirin LFB Biotechnologies SASU LG Life Sciences Lonza Biologics McDonnell Boehnen Hulbert & Berghoff LLP Medice Merck & Co. Merck KGaA Merck Serono Mérieux Alliance Ministry of Health, Labour and Welfare (MHLW) [Japan] Mitsubishi Tanabe Pharma Corporation Momenta Pharmaceuticals National Institute for Health and Clinical Excellence (NICE) [UK] Novartis Novo Nordisk Office of Technology Commercialisation [New York, USA] Pfizer PrimaPharm Qilu Ranbaxy Laboratories ratiopharm Roche Sandoz sanofi-aventis Schering-Plough SciGen [subsidiary of Bioton] Shantha Biotechnics Sidus Pharmaceutical Group Siegfried Biologics Stada Pharmaceuticals State Food and Drug Agency [China] Teva Pharmaceutical Industries Wockhardt World Health Organization (WHO) Wyeth Pharmaceuticals [now part of Pfizer] Zenotech Contact Person Bijal Patel bijal.patel@ +44(0)20 7549 9946 # # # Visiongain is an independent business information provider for the Telecoms, Pharmaceutical and Defence industries. We organise conferences, publish reports and newsletters, and provide consultancy services. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
